explore -WSS

explore

author：explore 2025-09-05 11:29:12 - browse：3

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

LONDON — Regulators in the U.K. on Thursday approved a CRISPR-based medicine to treat both sickle cell disease and beta thalassemia, making it the world’s first therapy built on the revolutionary gene-editing technology and ushering in a new era of genetic medicine.

The authorization of the therapy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is itself not a surprise. Clinical trials have shown the one-time treatment enabled many sickle cell patients to live free of debilitating pain crises and relieved thalassemia patients of needing regular blood transfusions, raising hopes that they have been effectively cured. But it also stands as a major achievement, coming just over a decade after the first and seminal lab experiments that showed CRISPR’s potential as a gene-editing tool were published.

In granting conditional approval to the therapy, which will have the brand name Casgevy and is also known as exa-cel, the U.K.’s Medicines and Healthcare products Regulatory Agency jumped ahead of its counterparts in the U.S. and Europe, which are also reviewing the medicine, in greenlighting the globe’s first CRISPR treatment. The MHRA’s authorization is for patients who are at least 12 years old.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： 'CMA Fest' 2023: How to watch, who is performing and more

WSS

Delta passengers in Vegas fall sick while waiting on flight in triple

Hormonal contraceptives don’t actually treat endometriosis

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Extensive review finds private equity owners jack up cost of care

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

entertainment

explore

hotspot

How to save PrEP access — and even expand it

Flagship Pioneering launches a new biotech in two countries

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

US jobless claims fall again as labor market continues to flash strength

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Rep. Raul Ruiz on the physician shortage and more

Hepatitis C has a cure — but many Americans still lack access to it

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

hotspot

U.K. Biobank has 500,000 peoples' genome sequences available

Rep. Raul Ruiz on the physician shortage and more

Hormonal contraceptives don’t actually treat endometriosis

Are infertility treatments 'essential' during the Covid

Extensive review finds private equity owners jack up cost of care

BIO selects John Crowley as new CEO

focus

Wikipedia

knowledge

knowledge